Addressing an important challenge faced: Tuning the potency, tolerability, and PK properties of ADC payloads to optimally address target and disease
18 Jun 2025
Cytotoxic Payload
- How do you optimize payload potency and DAR for specific target receptors and disease indications?
- How important is high antibody dose when targeting solid tumors?
- How to test ADC biophysical properties to ensure optimal pharmacokinetic properties of the ADC?
- Dual trigger ADCs: can you increase therapeutic index via multiple prodrug triggers?
- What is the next payload MoA that could drive ADCs forward beyond topoisomerase inhibitors?
Industry Expert
